Tag: Orphan Drug Designation
Sartar received Orphan Drug Designation for soft tissue sarcomas from the FDA
22.9.2025
As published last week, we are very proud to announce that Sartar was recently granted an new orphan drug designation (ODD) by the U.S. Food & Drug Administration (FDA) for the treatment of soft tissue sarcomas using our SAR003 drug candidate. This is a great milestone for our team and a significant regulatory protection for […]